文献速递免疫规划

同基因B16-F1细胞作为DC疫苗抗原源优于同种异体Cloudman细胞

Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.
PubMed 文献 · Vaccine · 2019-07-13

研究在C57BL/6小鼠中比较负载辐照同基因B16-F1或同种异体Cloudman黑色素瘤细胞的树突状细胞(DC)疫苗的保护效果,两细胞系均经全外显子组测序和RNAseq表征。两种肿瘤细胞成分均被DC高效内化并转运至MHC-II阳性管泡状区室,同种异体Cloudman负载DC诱导部分有效抗黑色素瘤保护,而同基因B16-F1负载DC建立更强更持久保护并诱导体液抗B16F1反应,提示新表位对持久保护是必需的。

要点

  • 同基因B16-F1负载DC诱导的保护比同种异体Cloudman负载DC更强且更持久。
  • 同种异体Cloudman与B16-F1共享黑色素细胞分化抗原、癌睾丸抗原等TAA,但仅同基因源提供新表位。
  • 两种辐照肿瘤细胞成分均被DC高效内化并转运至MHC-II阳性MIIC区室。

核心结论

  • 同基因B16-F1负载DC诱导更强更持久抗黑色素瘤保护并诱导体液抗B16F1反应,提示新表位对持久保护是必需的。

研究设计与样本

  • 在C57BL/6小鼠中比较负载辐照同基因B16-F1或同种异体Cloudman黑色素瘤细胞的DC疫苗保护效果。
  • 两细胞系均经全外显子组测序和RNAseq表征。

主要发现

  • 两种辐照肿瘤细胞成分均被DC高效内化并转运至MHC-II阳性管泡状区室(MIICs)。
  • 负载同种异体辐照Cloudman细胞的DC(DC-ApoNecALLO)诱导部分有效抗黑色素瘤保护。
  • 负载同基因B16-F1细胞的DC(DC-ApoNecSYN)建立更强更持久保护并诱导体液抗B16F1反应。

临床怎么用

  • 在DC疫苗设计中,同基因肿瘤细胞作为抗原源可能比同种异体细胞提供更持久的抗肿瘤保护。
  • 选择抗原源时需考虑同基因肿瘤细胞可提供新表位,而同种异体细胞仅提供共享TAA。

局限性

  • 研究仅在小鼠B16-F1黑色素瘤模型中进行,结论外推至其他肿瘤或人类需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A major obstacle to obtaining relevant results in cancer vaccination has been the lack of identification of immunogenic antigens. Dendritic cell (DC)-based cancer vaccines used preventively may afford protection against tumor inoculation, but the effect of antigen choice on anti-tumor protection is not clear. When using irradiated syngeneic tumor cells to load DCs, tumor self-antigens are provided, including tumor-associated antigens (TAAs) and neoantigens generated by tumor mutations. On the other hand, allogeneic tumor cells could only supply shared TAAs. To assess the advantages of each source in protective vaccination, we analyzed in C57BL/6 mice the effect of loading DCs with irradiated syngeneic B16-F1 or allogeneic Cloudman melanoma cells; both cell lines were characterized by whole exome sequencing and RNAseq. Tumor cell components from the two irradiated cell lines were efficiently internalized by DCs, and transported to MHC-class II positive tubulovesicular compartments (MIICs). DCs loaded with allogeneic irradiated Cloudman cells (DC-ApoNecALLO) induced a partially effective anti-melanoma protection, although Cloudman and B16-F1 cells share the expression of melanocyte differentiation antigens (MDAs), cancer-testis antigens (CTAs) and other TAAs. DCs loaded with syngeneic B16-F1 cells (DC-ApoNecSYN) established a more potent and long-lasting protection and induced a humoral anti-B16F1 response, thus suggesting that neoepitopes are needed for inducing long-lasting protection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mac Keon S, Bentivegna S, Levy EM, et al. Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model. Vaccine. 2019. PMID: 31307876. doi:10.1016/j.vaccine.2019.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。